|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12345678910111213...4647» |
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 (clinicaltrials.gov) - Dec 15, 2016
P1/2, N=12, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed | N=15 --> 12 | Trial primary completion date: Jun 2017 --> Dec 2016
- rilapladib (SB-659032) / GSK
Enrollment change, Trial withdrawal: Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers (clinicaltrials.gov) - Dec 13, 2016
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Recruiting --> Completed | N=15 --> 12 | Trial primary completion date: Jun 2017 --> Dec 2016 N=30 --> 0 | Not yet recruiting --> Withdrawn
- || KHK6640 / Kyowa Kirin
Enrollment closed, Trial primary completion date: A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Dec 8, 2016
P1, N=62, Active, not recruiting, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
N=30 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Apr 2017
- davunetide intranasal (AL-108) / Endo
Trial primary completion date: Davunetide (AL-108) in Predicted Tauopathies - Pilot Study (clinicaltrials.gov) - Dec 7, 2016
P2, N=12, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Apr 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- modafinil / Generic mfg.
Trial primary completion date: Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil (clinicaltrials.gov) - Dec 6, 2016
P4, N=48, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- || Trial primary completion date: Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis (clinicaltrials.gov) - Dec 2, 2016
P2, N=158, Recruiting, Sponsor: University of Miami
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Enrollment closed: The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (clinicaltrials.gov) - Dec 1, 2016
P=N/A, N=18, Active, not recruiting, Sponsor: Stanford University
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- | BN82451 / Ipsen
Trial completion, Trial primary completion date: Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients (clinicaltrials.gov) - Dec 1, 2016
P2a, N=25, Completed, Sponsor: Ipsen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2016
- Trial primary completion date: COST-TBI: Combined Transcranial Magnetic Stimulation and Cognitive Treatment in Blast Traumatic Brain Injury (clinicaltrials.gov) - Nov 29, 2016
P1/2, N=24, Recruiting, Sponsor: Boston Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2016 Trial primary completion date: May 2017 --> May 2018
- ||||| verubecestat (MK-8931) / Merck (MSD)
Enrollment closed: APECS: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (clinicaltrials.gov) - Nov 23, 2016
P3, N=1500, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: May 2017 --> May 2018 Recruiting --> Active, not recruiting
- Byetta (exenatide) / AstraZeneca
Trial completion, Trial primary completion date: A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease (clinicaltrials.gov) - Nov 22, 2016
P2, N=100, Completed, Sponsor: National Institute on Aging (NIA)
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Nov 2016
- Enrollment closed, Enrollment change, Trial primary completion date: Cataract Removal and Alzheimer's Disease (clinicaltrials.gov) - Nov 21, 2016
P=N/A, N=122, Active, not recruiting, Sponsor: University Hospitals Cleveland Medical Center
Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Nov 2016 Recruiting --> Active, not recruiting | N=210 --> 122 | Trial primary completion date: Jun 2016 --> Jan 2017
- |||| galantamine hydrobromide / Generic mfg., rivastigmine transdermal / Generic mfg.
Trial completion, Enrollment change: Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors (clinicaltrials.gov) - Nov 18, 2016
P4, N=52, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=210 --> 122 | Trial primary completion date: Jun 2016 --> Jan 2017 Recruiting --> Completed | N=110 --> 52
- Trial completion: MFYM - P: Move for Your Mind - Pilot Trial (clinicaltrials.gov) - Nov 17, 2016
P=N/A, N=19, Completed, Sponsor: University of Zurich
Recruiting --> Completed | N=110 --> 52 Active, not recruiting --> Completed
- lorazepam / Generic mfg.
Trial completion: The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms (clinicaltrials.gov) - Nov 10, 2016
P1, N=57, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change, Surgery: COGCAR: Characterization of Factors Influencing the Cognitive Decline in Patients With Coronary Artery Disease (clinicaltrials.gov) - Nov 9, 2016
P=N/A, N=155, Completed, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed Recruiting --> Completed | N=400 --> 155
- Trial primary completion date: Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=102, Completed, Sponsor: William Beaumont Hospitals
Recruiting --> Completed | N=400 --> 155 Trial primary completion date: Oct 2015 --> Mar 2016
- Trial primary completion date: Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198 (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=33, Active, not recruiting, Sponsor: National Eye Institute (NEI)
Trial primary completion date: Oct 2015 --> Mar 2016 Trial primary completion date: Oct 2016 --> Oct 2017
- modafinil / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill (clinicaltrials.gov) - Nov 4, 2016
P3, N=0, Withdrawn, Sponsor: Brigham and Women's Hospital
Trial primary completion date: Oct 2016 --> Oct 2017 N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2016 --> Jul 2015
- Trial completion, Trial primary completion date: Cognitive Impairment and Balance in Elderly (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=82, Completed, Sponsor: Universidad de Granada
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2016 --> Jul 2015 Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Apr 2015
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial primary completion date: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=450, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Apr 2015 Trial primary completion date: Dec 2017 --> Sep 2017
- Trial primary completion date: Exercise Effects in Huntington's Disease (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=40, Recruiting, Sponsor: University of Zurich
Trial primary completion date: Dec 2017 --> Sep 2017 Trial primary completion date: Dec 2015 --> Jun 2017
- Enrollment change, Trial termination, Trial primary completion date: Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=55, Terminated, Sponsor: University of Chicago
Trial primary completion date: Dec 2015 --> Jun 2017 N=150 --> 55 | Recruiting --> Terminated | Trial primary completion date: Nov 2013 --> Sep 2010
- Trial primary completion date: CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=80, Enrolling by invitation, Sponsor: Washington University School of Medicine
N=150 --> 55 | Recruiting --> Terminated | Trial primary completion date: Nov 2013 --> Sep 2010 Trial primary completion date: Jul 2016 --> Feb 2017
- quetiapine / Generic mfg.
Enrollment closed: Efficacy of Quetiapine for Pediatric Delirium (clinicaltrials.gov) - Nov 1, 2016
P1/2, N=50, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Jul 2016 --> Feb 2017 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: A Pre-Cellular Therapy Observational Study in Early Huntington's Disease (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=29, Completed, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=40 --> 29
- Trial primary completion date: Neurological Complications - Pulmonary Transplant (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=28, Terminated, Sponsor: Hopital Foch
Active, not recruiting --> Completed | N=40 --> 29 Trial primary completion date: Mar 2013 --> Dec 2013
- Trial completion, Trial primary completion date: Deep Brain Stimulation for Patients With Dementia With Lewy Bodies (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=6, Completed, Sponsor: University College, London
Trial primary completion date: Mar 2013 --> Dec 2013 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Oct 2016
- | donepezil / Generic mfg., rosiglitazone / Generic mfg.
Phase classification: REFLECT-2: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=1496, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Oct 2016 Phase classification: P3 --> P=N/A
- Trial completion, Trial primary completion date: BWP-AD: Enhancing Consent for Alzheimer's Research (clinicaltrials.gov) - Oct 28, 2016
P=N/A, N=252, Completed, Sponsor: University of California, San Diego
Phase classification: P3 --> P=N/A Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Sep 2012
- Trial completion: fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=390, Completed, Sponsor: University of Wisconsin, Madison
Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Sep 2012 Active, not recruiting --> Completed
- Trial completion, Enrollment change: OPHELIE-COG: Pre-stroke Cognitive Status and Thrombolytic Therapy (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=205, Completed, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=1040 --> 205
- Enrollment closed, Trial primary completion date: Implementation of a Multicomponent Intervention to Prevent Physical Restraints in Nursing Home Residents (IMPRINT) (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=10800, Active, not recruiting, Sponsor: University of Luebeck
Active, not recruiting --> Completed | N=1040 --> 205 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2017
- Biomarker, Trial completion, Trial primary completion date: Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=80, Completed, Sponsor: University of South Florida
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2017 Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2016
- Trial completion: Short-term Caregiver Psychotherapy (clinicaltrials.gov) - Oct 26, 2016
P2, N=13, Completed, Sponsor: University of Rostock
Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2016 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=102, Completed, Sponsor: William Beaumont Hospitals
Active, not recruiting --> Completed Enrolling by invitation --> Completed | N=1000 --> 102 | Trial primary completion date: Dec 2016 --> Oct 2015
- Trial completion, Enrollment change, Trial primary completion date: Deep Brain Stimulation for the Treatment of Alzheimer's Disease (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=3, Completed, Sponsor: Ali Rezai, MD
Enrolling by invitation --> Completed | N=1000 --> 102 | Trial primary completion date: Dec 2016 --> Oct 2015 Recruiting --> Completed | N=10 --> 3 | Trial primary completion date: Jan 2017 --> Jan 2016
- Enrollment closed, Enrollment change: HIAD: Hearing Instruments in Alzheimer's Disease (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=25, Active, not recruiting, Sponsor: Phonak AG, Switzerland
Recruiting --> Completed | N=10 --> 3 | Trial primary completion date: Jan 2017 --> Jan 2016 Recruiting --> Active, not recruiting | N=120 --> 25
- Trial completion: Meaningful Activity Intervention for Persons With Mild Cognitive Impairment (clinicaltrials.gov) - Oct 25, 2016
P1, N=80, Completed, Sponsor: Indiana University
Recruiting --> Active, not recruiting | N=120 --> 25 Active, not recruiting --> Completed
- Trial primary completion date: Study to Evaluate Coconut Oil for Alzheimer's Disease (clinicaltrials.gov) - Oct 21, 2016
P2/3, N=65, Recruiting, Sponsor: University of South Florida
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Jun 2018
- Enrollment open, Trial primary completion date, Surgery: The Delirium-CS Canada Study (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=234, Enrolling by invitation, Sponsor: St. Boniface General Hospital Research Centre
Trial primary completion date: Dec 2016 --> Jun 2018 Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Jan 2015 --> Jan 2017
- | naproxen / Generic mfg.
Trial completion: Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) (clinicaltrials.gov) - Oct 18, 2016
P3, N=2625, Completed, Sponsor: Seattle Institute for Biomedical and Clinical Research
Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Jan 2015 --> Jan 2017 No longer recruiting --> Completed
- | Cerebrate (pinitol) / Humanetics
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Oct 17, 2016
P2, N=30, Completed, Sponsor: Humanetics Corporation
No longer recruiting --> Completed Recruiting --> Completed | N=40 --> 30 | Initiation date: Aug 2010 --> Apr 2007 | Trial primary completion date: Aug 2013 --> Jun 2014
- Trial primary completion date: PACR-AD: Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease (clinicaltrials.gov) - Oct 14, 2016
P=N/A, N=40, Recruiting, Sponsor: Posit Science Corporation
Recruiting --> Completed | N=40 --> 30 | Initiation date: Aug 2010 --> Apr 2007 | Trial primary completion date: Aug 2013 --> Jun 2014 Trial primary completion date: Sep 2016 --> May 2017
- |||| PF-02545920 / Pfizer
Trial completion: Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease (clinicaltrials.gov) - Oct 14, 2016
P2, N=272, Completed, Sponsor: Pfizer
Trial primary completion date: Sep 2016 --> May 2017 Recruiting --> Completed
- | Trial termination: HORIZON PLUS: An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease (clinicaltrials.gov) - Oct 12, 2016
P3, N=362, Terminated, Sponsor: Medivation, Inc.
Recruiting --> Completed Completed --> Terminated
- citalopram / Generic mfg., venlafaxine / Generic mfg., donepezil / Generic mfg.
Trial completion: DEP-CI: Combination Treatment Study for Memory Impairment and Depression (clinicaltrials.gov) - Oct 12, 2016
P4, N=86, Completed, Sponsor: New York State Psychiatric Institute
Completed --> Terminated Active, not recruiting --> Completed
- memantine ER / Generic mfg., galantamine extended release / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (clinicaltrials.gov) - Oct 12, 2016
P2, N=3, Terminated, Sponsor: Sheppard Pratt Health System
Active, not recruiting --> Completed N=10 --> 3 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Jul 2016; Funding no longer available and PI no longer working at the institution
- Trial primary completion date: The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=18, Recruiting, Sponsor: Stanford University
N=10 --> 3 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Jul 2016; Funding no longer available and PI no longer working at the institution Trial primary completion date: Jun 2016 --> Nov 2016
- Trial completion: Cytokines and Cognitive Decline in Alzheimer's Disease (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=133, Completed, Sponsor: Poitiers University Hospital
Trial primary completion date: Jun 2016 --> Nov 2016 Recruiting --> Completed